The Technical AnalystExchange: EURONEXT Industry: Medical Devices
Mauna Kea Technologies Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.32% €0.622
America/New_York / 7 aug 2023 @ 10:09
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 30.17 mill |
| EPS: | -0.250 |
| P/E: | -2.49 |
| Earnings Date: | Sep 27, 2023 |
| SharesOutstanding: | 48.50 mill |
| Avg Daily Volume: | 0.159 mill |
| RATING 2023-09-04 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 4/20 | 2/21 | 4/21 | 2/22 | 4/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.49 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -2.49 | industry: PE 60.12 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 0.584 - 0.602 ( +/- 1.52%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €0.622 (0.32% ) |
| Volume | 0.0099 mill |
| Avg. Vol. | 0.159 mill |
| % of Avg. Vol | 6.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MKEA.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MKEA.PA
Mauna Kea Technologies SA develops and markets medical devices in Europe, the Middle East, Africa, the United States, Latin America, and Asia. The company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product is Cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. The company was incorporated in 2000 and is headquartered in Paris, France.